Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

Autor: Shah NN; Medical College of Wisconsin, Milwaukee, WI. nishah@mcw.edu., Wang M; MD Anderson Cancer Center, Houston, TX., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY., Patel K; Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Wierda WG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Ujjani CS; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford., Zinzani PL; Institute of Hematology 'Seragnoli' University of Bologna, Bologna., Alencar AJ; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Ghia P; Universita Vita-Salute San Raffaele, Milano, Italy; IRCCS Ospedale San Raffaele, Milano., Lamanna N; New York-Presbyterian Columbia University Medical Center, New York, NY., Hoffmann MS; Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL., Flinn I; Sarah Cannon Research Institute, Nashville, TN., Gerson JN; Lymphoma Program, Abramson Cancer Center, Philadelphia, PA., Ma S; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL., Coombs CC; University of California Irvine, Irvine, CA., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Fakhri B; Division of Hematology at Stanford University School of Medicine, Stanford, CA., Kim WS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul., Barve MA; Mary Crowley Cancer Research Center, Dallas, TX., Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland., Munir T; Department of Haematology, St. James's University Hospital, Leeds., Thompson MC; Memorial Sloan Kettering Cancer Center, New York, NY., Tsai DE; Loxo@Lilly, Indianapolis, IN., Bao K; Loxo@Lilly, Indianapolis, IN., Cangemi NA; Loxo@Lilly, Indianapolis, IN., Kherani JF; Loxo@Lilly, Indianapolis, IN., Walgren RA; Loxo@Lilly, Indianapolis, IN., Han H; Loxo@Lilly, Indianapolis, IN., Ruppert AS; Eli Lilly and Company, Indianapolis, IN., Brown JR; Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Publikováno v: Haematologica [Haematologica] 2024 Oct 03. Date of Electronic Publication: 2024 Oct 03.

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.

Autor: Tao JJ; Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Cangemi NA; Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Makker V; Gynecologic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Cadoo KA; Gynecologic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Liu JF; Dana-Farber Cancer Institute, Boston, Massachusetts., Rasco DW; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Navarro WH; Atara Biotherapeutics, South San Francisco, California., Haqq CM; Atara Biotherapeutics, South San Francisco, California., Hyman DM; Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. hymand@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Sep 15; Vol. 25 (18), pp. 5458-5465. Date of Electronic Publication: 2019 May 08.

An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.

Autor: Liang LW; Weill Cornell Medical College; and †Gynecologic Medical Oncology Service, Department of Medicine, ‡Epidemiology and Biostatistics, §Gynecologic Service, Department of Surgery, and ∥Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Perez AR, Cangemi NA, Zhou Q, Iasonos A, Abu-Rustum N, Alektiar KM, Makker V

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2016 Mar; Vol. 26 (3), pp. 497-504.